Detail akcie Alkermes online

Business Summary: Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Alkermes Plc revenues decreased 6% to $1.56B. Net income before extraordinary items decreased 28% to $372.1M. Revenues reflect Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA segment decrease of 51% to $236.4M, Manufacturing-RISPERDAL CONSTA segment decrease of 36% to $23.2M, United States segment decrease of 5% to $1.41B, Rest of the World segment decrease of 14% to $146.2M.